About sangamo therapeutics inc. - SGMO
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The firm focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
SGMO At a Glance
Sangamo Therapeutics, Inc.
501 Canal Boulevard
Richmond, California 94084
| Phone | 1-510-970-6000 | Revenue | 39.55M | |
| Industry | Biotechnology | Net Income | -122,932,000.00 | |
| Sector | Health Technology | Employees | 142 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SGMO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.975 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.23 |
| Enterprise Value to Sales | 3.123 |
| Total Debt to Enterprise Value | 0.217 |
SGMO Efficiency
| Revenue/Employee | 278,535.211 |
| Income Per Employee | -865,718.31 |
| Receivables Turnover | 3.762 |
| Total Asset Turnover | 0.477 |
SGMO Liquidity
| Current Ratio | 0.844 |
| Quick Ratio | 0.844 |
| Cash Ratio | 0.493 |
SGMO Profitability
| Gross Margin | 80.78 |
| Operating Margin | -273.068 |
| Pretax Margin | -312.247 |
| Net Margin | -310.811 |
| Return on Assets | -148.264 |
| Return on Equity | -2,891.837 |
| Return on Total Capital | -981.336 |
| Return on Invested Capital | -410.814 |
SGMO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 213.898 |
| Total Debt to Total Assets | 44.278 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 200.311 |